某醫(yī)藥公司產(chǎn)品組合優(yōu)化(內(nèi)部資料)(參考版)
2025-01-04 01:39本頁(yè)面
【正文】 Managers need to relax assumptions used earlier, for example,? Allow each approach in each indication to have unique probability of success Solution: A general modelJune 48, 2023 17From Pipelines to PortfoliosAn Application of the General ModelWhat we show hereAn optimization exercise based on GlaxoSmithKline Phase III Subportfolio (December 2023)? The predicted distribution of market payoffs of its current portfolio based on our portfolio model? If GSK were interested in licensing two additional Phase III pounds, which pounds it should add to its existing portfolio, under 3 different 2tier objectivesWhat we do not show here (but could be done similarly)Optimization of earlier stage subportfoliosOptimization based on other types of strategic objectives, .,? Discontinuing some current projects (portfolio audit)? Optimal budget (determine budget based on strategic objectives)June 48, 2023 18GSK Phase III SubportfolioFrom GSK Website? A, B, …J only denote the sequence of indications in a given area, the same letter represents different indication in different area.June 48, 2023 19GSK Phase III SubportfolioA Numeric Matrix Representation? A, B, …J only denote the sequence of indications in a given area, the same letter represents different indication in different area.? The number in a cell represents the number of approaches supported targeting that particular indicationJune 48, 2023 20Distribution of Market Payoff Given GSK’s Current Phase III SubportfolioJune 48, 2023 21Optimization ScenariosGSK wants to license in two pounds to add to its existing Phase III subportfolio, which pounds should be licensed under each of the three different 2tier strategic objectives:1. Maximize expected NPV, conditional on it will obtain
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1